

Alberta Retired Teachers' Association (ARTA), Group 19930 "A" Sections Only

As a reminder, effective January 1, 2021, ARTA, group 19930 "A" sections direct bill drug claims are to be submitted to Green Shield Canada. ARTA is now self-administering its Retiree Benefits Plan and Alberta School Employee Benefit Plan (ASEBP) is no longer providing this service. Additional information on claiming can be found in Benefact Number 917, December 2020.

Removal of Temporary Benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortages for Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Aldactone 100 mg Tablet (DIN 00285455) manufactured by Pfizer Canada Inc. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Teva Canada Limited has advised Alberta Blue Cross that the shortage for Teva-Spironolactone 100 mg Tablet (DIN 00613223) has been resolved.

As a result, Aldactone 100 mg Tablet (DIN 00285455) will no longer be considered a temporary benefit for the ADBL **after January 15, 2021**. The following grouping was removed from the Critical Supply Product List **December 18, 2020**.

Due to the shortages for Mint-Spironolactone 25 mg Tablet (DIN 02488140) manufactured by Mint Pharmaceuticals Inc. and Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited, Aldactone 25 mg Tablet (DIN 00028606) manufactured by Pfizer Canada ULC. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Teva Canada Limited has advised Alberta Blue Cross that the shortage for Teva-Spironolactone 25 mg Tablet (DIN 00613215) has been resolved.

As a result, Aldactone 25 mg Tablet (DIN 00028606) will no longer be considered a temporary benefit for the ADBL **after January 21, 2021**. The following grouping was removed from the Critical Supply Product List **December 18, 2020**.

continued next page

continued from previous page

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Tecnal-C 1/2 Capsule (DIN 00608181) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 25, 2021**. The following grouping was removed from the Critical Supply Product List **December 22, 2020**.

BUTALBITAL/ CODEINE PHOSPHATE/ ASA/ CAFFEINE

50 MG / 30 MG / 330 MG / 40 MG CAPSULE

00000608181	TEVA-TECNAL-C 1/2	TEV	\$ 1.9285
00000176206	FIORINAL-C 1/2	ARA	\$ 2.2299

Alberta Blue Cross has been advised by Actavis Pharma Company and Pharmascience Inc. that the shortages for Act Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02453916) and pms-Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02424878) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 18, 2021**. The following grouping was removed from the Critical Supply Product List **December 17, 2020**.

BUPRENORPHINE HCL / NALOXONE HYDROCHLORIDE DIHYDRATE

8 MG / 2 MG SUBLINGUAL TABLET

00002453916	ACT BUPRENORPHINE/NALOXONE	APH	\$ 2.3650
00002424878	PMS-BUPRENORPHINE/NALOXONE	PMS	\$ 2.3650
00002295709	SUBOXONE	IUK	\$ 4.8293

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

